City of Hope Southwest Oncology Group Clinical Trials

这项提案的总体目标是支持希望之城国家医疗机构的参与 西南肿瘤研究组(SWOG)研究性临床试验中心(COH)。COH，An NCI指定的综合癌症中心，为临床研究提供了强有力的领导 SWOG在过去六年中的活动。在COH的SWOG成员提供了大量的科学 为开发恶性血液病新的治疗方案以及各方面提供投入 为该组织提供高剂量化疗和干细胞支持；此外，肿瘤学方面的专业知识 药理学、细胞遗传学、免疫疗法、泌尿生殖道癌、妇科病理学和肿瘤 生物将继续支持SWOG的试点方案制定以及参与整个集团 第二阶段和第三阶段研究。来自COH的SWOG成员也为研究活动做出了重大贡献 在肿瘤外科和癌症预防方面。COH的医生和科学家增加了他们的领导力 在本供资周期内在SWOG内开展的活动，增加了生殖泌尿外科的主席职位 委员会的睾丸癌症小组委员会和新成立的早期治疗委员会将继续 担任骨髓和干细胞移植委员会和妇科委员会主席 委员会的病理学和肿瘤生物学小组委员会。除了这些领导职位外， SWOG内部COH调查人员的科学生产力持续提高。在上一次的时候 对COH参与SWOG的竞争性审查，9名COH调查人员发表了18篇论文和14篇 报告SWOG临床研究的摘要；在过去的六年中，12名COH调查人员 在高质量的同行评议出版物上发表了31篇论文和28篇摘要，描述了SWOG的研究。 基于病理学、外科肿瘤学、 放射肿瘤学、癌症控制以及内科肿瘤学、实验治疗学和 致力于SWOG追求的研究的血液学，实质性的科学领导 COH对SWOG临床试验的患者收益可以预测将在即将到来的资金中继续下去 周而复始。此外，COH参与SWOG设计的创新治疗概念将 在大南加州地区扩大癌症研究护理的可获得性。

The overall objective of this proposal is to support the participation of the City of Hope National Medical Center (COH) in the investigational clinical trials of the Southwest Oncology Group (SWOG). The COH, an NCI-designated Comprehensive Cancer Center, has supplied strong leadership for the clinical research activities of SWOG during the past six years. SWOG members at COH have provided substantial scientific input into the development of new therapeutic programs for hematological malignancies as well as all aspects of high-dose chemotherapy with stem cell support for the group; in addition, expertise in oncologic pharmacology, cytogenetics, immunotherapy, genitourinary cancers, and gynecologic pathology and tumor biology will continue to support pilot protocol development for SWOG as well as participation in group-wide phase II and phase III studies. SWOG members from COH also contribute substantially to research activities in oncologic surgery and cancer prevention. COH physicians and scientists have increased their leadership activities within SWOG during the current funding cycle, adding the chairmanships of the Genitourinary Committee's Testis Cancer Subcommittee and the newly formed Early Therapeutics Committee to continuing service as chairs of the Bone Marrow and Stem Cell Transplantation Committee, and the Gynecology Committee's Pathology and Tumor Biology Subcommittees. In addition to these leadership positions, the scientific productivity of COH investigators within SWOG has continued to increase. At the time of the last competitive review of COH's participation in SWOG, 9 COH investigators had published 18 papers and 14 abstracts reporting SWOG clinical investigations; over the past six years, 12 COH investigators have published 31 papers and 28 abstracts describing SWOG research in high-quality, peer-reviewed publications. Based on the presence of a dedicated, multidisciplinary team of physicians in Pathology, Surgical Oncology, Radiation Oncology, and Cancer Control as well as Medical Oncology, Experimental Therapeutics, and Hematology who are committed to the investigations pursued by SWOG, substantive scientific leadership of and patient accrual to SWOG clinical trials by the COH can be predicted to continue over the coming funding cycle. Furthermore, participation by the COH in the innovative treatment concepts devised by SWOG will broaden the availability of investigational cancer care in the greater Southern California region.